23rd May 2007
[QUOTE]CCB's have been linked to an increased risk for heart attacks, especially in women.
Hi Sonia, :)
First of all, CCBs should be considered first-line antihypertensive medication because of they are effective and have mild and reversible side effects. They can be used as a stand alone treatment or in combination with diuretics. If you start out with CCBs, you might not need any diuretics (which have more serious side effects in some people).
....The drug in question, short-acting nifedipine, should be used with great caution or NOT AT ALL, especially in high doses,... -warned the Heart, Lung and Blood Institute back then. (I believe the doctors don't prescribe it anymore.)
There were smaller clinical trials and several studies done, the results of which, as we hear now, were not intererpreted with the right perspective.
You can find and read the original published studies and the comments and follow-ups published afterwards. A good place to start would be JAMA and circulation AHA journals and an Archive of Internal Medicine.
Importantly: The nifedipine finding cannot be necessarily generalized to any other CCB including longer acting forms of nifedipine and short acting formulas of diltiazem and verapamil....
So it was probably just that one specific drug whose suitability was being questioned.
This drug was also linked to higher frequency of cancer and found unsuitable for use in people with HF and structural heart problems. I don't know how long ago this was and did not read the studies. Don't quote me on it. In any case, I think the short acting version is not produced commercially anymore.
Good luck with your treatment, Sonia!
Flowergirl
Hi Sonia, :)
First of all, CCBs should be considered first-line antihypertensive medication because of they are effective and have mild and reversible side effects. They can be used as a stand alone treatment or in combination with diuretics. If you start out with CCBs, you might not need any diuretics (which have more serious side effects in some people).
....The drug in question, short-acting nifedipine, should be used with great caution or NOT AT ALL, especially in high doses,... -warned the Heart, Lung and Blood Institute back then. (I believe the doctors don't prescribe it anymore.)
There were smaller clinical trials and several studies done, the results of which, as we hear now, were not intererpreted with the right perspective.
You can find and read the original published studies and the comments and follow-ups published afterwards. A good place to start would be JAMA and circulation AHA journals and an Archive of Internal Medicine.
Importantly: The nifedipine finding cannot be necessarily generalized to any other CCB including longer acting forms of nifedipine and short acting formulas of diltiazem and verapamil....
So it was probably just that one specific drug whose suitability was being questioned.
This drug was also linked to higher frequency of cancer and found unsuitable for use in people with HF and structural heart problems. I don't know how long ago this was and did not read the studies. Don't quote me on it. In any case, I think the short acting version is not produced commercially anymore.
Good luck with your treatment, Sonia!
Flowergirl
